Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Business Wire
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET.The U.S. Food and Drug Administration assigned taletrectinib’s New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025.Investors and the general public are invited to listen to a live webcast of the call at https://investors.nuvationbio.com/investors/. Materials related to the call will be available prior to the start of the conference call. A replay of the webcast will be available after the conference call concludes.About Nuvation BioNuvation Bio is a global oncology company focused on solving some of the toughest challenges in cancer treatment by deve
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Has Nuvation Bio's 234% Surge in 2025 Already Reflected Its Growth Potential? [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NUVB): Reassessing Valuation After a 78% Monthly Surge in the Share Price [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NYSE:NUVB) had its price target raised by analysts at HC Wainwright from $10.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug ListPR Newswire
- Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result [Yahoo! Finance]Yahoo! Finance
NUVB
Earnings
- 11/3/25 - Beat
NUVB
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/26/25 - Form 4
- NUVB's page on the SEC website